LYTGOBI Taiho Pharma Oceania Pty Ltd
Product name
LYTGOBI
Sponsor
Accepted date
Apr-2024
Active ingredients
futibatinib
Proposed indication
For the treatment of metastatic cholangiocarcinoma (CCA).
Application type
A (new medicine)
Publication date
Apr-2024
Orphan drug
Sponsors receive a fee waiver to help bring medicines for a small population to market.
Provisional registration
Involves early access to vital and life-saving medicines through time-limited registration.